A B S T R AC T
Background. Proteinuria is the predominant risk factor for renal disease progression in Fabry disease (FD). When urine protein excretion is controlled to <0.50 g/24 h, the rate loss of glomerular filtration rate (GFR) is not significantly different from 0. However, enzyme replacement therapy (ERT) alone does not decrease proteinuria and it has been recommended that patients receiving ERT also receive anti-renin-angiotensin system (RAS) therapy. Emerging evidence show that paricalcitol (PCT) reduces proteinuria in the presence of intensified inhibition of RAS; however, there is no evidence in FD. We evaluated the antiproteinuric effect of PCT in FD patients with proteinuria >0.50 g/24 h persisting despite ERT and anti-RAS therapy titrated to maximum tolerated dosage. Methods. Fifteen FD patients were selected and studied in the first 6 months of add-on oral PCT (1 µg/day) and, in order to verify the dependence of proteinuria reduction on PCT, 3 months after drug withdrawal. Results. At baseline, proteinuria was 1.3 ± 0.6 g/24 h. Six months of add-on PCT significantly decreased proteinuria to 0.4 ± 0.3 g/24 h, with levels <0.50 g/24 h achieved in four patients at Month 1, six at Month 3, and in 12 by Month 6, in the absence of changes to BP and GFR. Proteinuria recovered to basal value after drug withdrawal.
Conclusions. In conclusion, our study is the first evidence that PCT is effective in reducing proteinuria in FD patients in the presence of ERT and anti-RAS therapy.
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I N T R O D U C T I O N
Fabry disease (FD) is an X-linked disorder caused by lysosomal α-galactosidase A deficiency, with subsequent deposition of undegraded glycosphingolipid products in multiple organs. Progressive nephropathy is one of the main features of FD [1] . The decline in renal function in FD is adversely affected by male gender, advanced chronic kidney disease (CKD), hypertension and, in particular, severe proteinuria. Studies of patients with FD have identified proteinuria as a major risk factor for renal disease progression. Therefore treatment of proteinuria is one of the goals in management of FD patients. When urine protein excretion is controlled to <0.50 g/24 h, the rate of loss of estimated glomerular filtration rate (eGFR) was not significantly different from 0 [2] .
Currently, enzyme replacement therapy (ERT) is the only specific treatment for FD patients, which has been shown to slow the progression of Fabry nephropathy [3] . However, ERT alone does not appear to reduce proteinuria [4, 5] and it has been recommended that patients receiving ERT also receive angiotensin-converting-enzyme inhibitors or angiotensin receptor blockers (ACEi/ARBs). Multiple blockade of reninangiotensin system (RAS) allows an additional decrement of proteinuria which is, however, still limited and heterogeneous, with many patients being left with significant residual proteinuria [6] ; therefore, novel ways of proteinuria treatment are being studied.
Recent studies have shown broad-ranging activities of vitamin D that extend beyond the regulation of calcium and phosphorus metabolism mediated by vitamin D receptor [7] . These so-called non-calcemic activities include regulation of renal and cardiovascular functions and modulation of immune responses. Several data have shown that paricalcitol (PCT) reduces proteinuria in several models of kidney disease, likely through the nuclear factor κB pathway and the RAS [8] [9] [10] [11] [12] .
However, the effects of these strategies in patients with FD nephropathy are unknown.
The aim of our study was to evaluate the effect of PCT on proteinuria in FD patients with proteinuria >0.5 g/24 h persisting despite the ERT and anti-RAS therapy titrated to maximum tolerated dosage.
M AT E R I A L S A N D M E T H O D S
Study population This is a prospective, observational study. Between December 2011 and December 2013, 49 patients with FD were seen at the Fabry Center of the Federico II University of Naples and considered for recruitment. The inclusion criteria were: (i) genetically proven FD, (ii) stable dose of ERT for at least 12 months, (iii) stable dose of ACEi or ARB titrated to maximum tolerated dosage for at least 6 months and (iv) persistent proteinuria >0.50 g/24 h despite the use of ERT and ACEi/ARBs in two consecutive samples within 12 weeks. Exclusion criteria were: steroid/immunosuppressive treatment, eGFR changes >30% in the past 3 months, parathormone (PTH) levels <20 pg/mL, serum phosphorus >5.0 mg/dL, serum calcium (adjusted for albumin) >10.0 mg/dL, active malignancy. On the basis of such criteria, 15 patients were enrolled in the study and written informed consent was obtained from all of them ( Figure 1 ). The study was approved by the local medic ethics committee and was in adherence with the Declaration of Helsinki.
Study procedures
In patients identified by the inclusion criteria, data were collected at enrolment ( prior to ACEi/ARB maximum dosage therapy), at baseline ( prior to first administration of PCT), during administration of oral PCT (after 1, 3 and 6 months) and 3 months after PCT withdrawal.
At baseline, 15 FD patients were selected and studied in the first 6 months of add-on oral PCT (1 µg/day) and, in order to verify the dependence of proteinuria reduction on PCT, 3 months after drug withdrawal. None of the patients had received a vitamin D analogue at least 1 month before beginning enrolment in the study.
Intensification of anti-RAS therapy
To achieve remission of proteinuria, anti-RAS therapy was titrated during enrolment to the full dose suggested by manufacturer's recommendations, or at the highest tolerated dose ( presence of symptomatic hypotension, acute eGFR decrease >30% or serum potassium >5.5 mmol/L). The patients were first administered a single anti-RAS agent (either ACEi or ARB), opportunely titrated; if proteinuria still persisted above the target, ACEi with ARB were combined. In case of low blood pressure (BP) levels, antihypertensive drugs other than anti-RAS were downtitrated or eliminated.
Add-on PCT
PCT was administered at a dosage of 1 µg/day; this dosage was chosen as it is not associated with excessive decline of PTH levels in most patients [9, 11] .
Data collection
Demographic and clinical data were obtained at baseline (Tables 1 and 2 ). At each control a complete clinical evaluation was performed, including body weight, BP and adjustments of therapy. Moreover, we evaluated 24-h urinary proteins, and in venous plasma or serum the following chemistries: creatinine, calcium, phosphate, albumin and PTH. Renal function was expressed as eGFR, calculated with Modification of Diet in Renal Disease equation.
Standard laboratory procedures were used for blood and urinary measurements.
Urine collections were considered inaccurate, and repeated, if the value of measured creatinine excretion rate fell outside the normal range.
Statistics
Variables are reported as mean and standard deviation (SD) or as median and interquartile range. Means are compared by paired or unpaired Student t-test and McNemar or chi-square test for categorical variables. ANOVA for repeated measures with Bonferroni as post hoc test are also used where appropriate. A two-tailed P-value of <0.05 is considered significant. Data are analysed using SPSS 20.0 (SPSS, Inc., Chicago, IL, USA).
R E S U LT S

Data at enrolment
We studied 15 patients identified by the inclusion criteria (Tables 2 and 3) .
At time of enrolment (9 months prior to study baseline), the median age for the eight men and the seven women was 42.7 ± 10.5 years. Eight families with distinct mutations were represented; the clinical manifestations were different, with multiple organ involvement in addition to Fabry nephropathy ( Table 2 ). All patients were treated with a stable dose of ERT for at least 12 months. Eight patients were treated with agalsidase beta and seven with agalsidase alfa, and the mean duration of ERT was 72.1 ± 36.8 months (median 60 months). Most patients were on antihypertensive therapy before enrolment; the mean number of antihypertensive drugs was 1.1 ± 0.6; ACEi/ARBs, however, were not used in five patients or used at low dosage in the remaining 10 patients (Table 3 ).
Data at baseline
At baseline, the mean number of antihypertensive drugs was 1.7 ± 0.7. The increase in number of BP lowering drugs, observed at baseline versus enrolment visit, was due to the larger use of anti-RAS agents. At baseline, in fact, all patients were treated with anti-RAS therapy at full dose: nine patients were under multiple blockade of RAS, and the remaining six were under a single anti-RAS agent. Intensification of RAS therapy was also obtained in these six patients administered a single anti-RAS agent; at enrolment, in fact, these drugs were not used in five patients or used at low dosage in the remaining patients, while at baseline all patients were treated with RAS blockers at full dose. In these six patients, combined therapy was considered unfeasible because adding the second anti-RAS agent had been associated with hypotension (n = 5) and hyperkalaemia (n = 1). Intensification of RAS was associated with a significant decrease in proteinuria (1.34 ± 0.6 mg/24 h, P < 0.001 versus enrolment), which still remained >0.5 g/24 h, and of BP (108/63 ± 6/4 mmHg, P < 0.001 versus enrolment), without changes in GFR (P = 0.3) ( Table 3 ).
Data at follow-up
As reported in Table 4 , add-on PCT was associated with a progressive decline in PTH levels that, however, did not decrease below the lower limit of normal range (20 pg/mL) in any patient. Serum calcium and phosphate remained within normal range in all patients (Tables 3 and 4) .
Add-on PCT induced a progressive decrease of proteinuria to 0.4 ± 0.3 g/24 h (P < 0.001) ( Table 4 ). The individual values at enrolment, at baseline and at the end of follow-up period are shown in Table 3 and in Figure 2 . Remission of proteinuria to values <0.5 g/24 h was achieved in four patients at Month 1 (26.7%), six at Month 3 (40%) and in 12 at Month 6 (80%). The mean reduction of proteinuria after 6 months of PCT was 68%. No correlation was found between percentage change in proteinuria, BP and eGFR (r = 0.16, P = 0.34). The first dose of PCT (1 µg/day) did not change throughout the 6 months of follow-up in all the patients.
Data after PCT withdrawal
To verify the dependence of proteinuria reduction on PCT, we evaluated the change of proteinuria 3 months after drug withdrawal. In all the patients, proteinuria recovered to baseline (Tables 3 and 4 and Figures 2 and 3 ).
D I S C U S S I O N
This study has shown that treatment with 1 µg PCT significantly reduces proteinuria in patients with FD nephropathy who were on a stable dose of ACEi and/or ARBs titrated to maximum tolerated dosage.
Early observational studies of vitamin D supplementation in patients have indicated the capacity of activators of the vitamin D receptor (VDRA) to decrease proteinuria (range 17-61%) in a number of kidney disease, irrespective of the level of renal insufficiency (stage 2-5), of its primary diagnosis and of the previous or concomitant use of anti-RAS agents [8] [9] [10] [11] [12] . Of note, higher doses of PCT (2 versus 1 µg/day) in diabetic CKD patients further decreased urinary protein excretion with no additional metabolic or clinical side effects, suggesting the possibility of safely increasing PCT doses, if needed.
However, the exact effect of PCT in patients with FD nephropathy was undefined. The presence of proteinuria >0.5 g/24 h identifies a subgroup of FD patients which carries the highest risk of renal disease progression. In these patients, minimizing RAS activity is a main target of treatment. Moreover, recent evidence highlighted the very high prevalence of vitamin D insufficiency and deficiency in FD patients [13] . In fact, due to symptoms such as heat intolerance and the inability to sweat, Fabry patients tend to avoid sunlight exposure. Often, patients also suffer from malabsorptive gastrointestinal disease. Both conditions may contribute to a deficiency in vitamin D. It has been recently evidenced, moreover, that vitamin D deficiency is strongly associated with cardiomyopathy and adverse clinical symptoms in FD patients [14] . 9.2 ± 0.7 9.3 ± 0.6 9.3 ± 0.6 9.4 ± 0.5 9.4 ± 0.4 9.4 ± 0.3 Serum phosphorus (mg/dL) 3.9 ± 0.6 3.9 ± 0.7 3.9 ± 0. VDRAs appear to mediate antiproteinuric effects by several mechanisms. First, in cultured human podocytes, VDRA prevented lyso-Gb-3-induced, TGFβ1-mediated, up-regulation of extracellular matrix proteins [15] . Experimental studies have shown that vitamin D acts as a strong negative endocrine regulator of the RAS and functions mainly to suppress renin production [14] . Therefore, the effects on RAS inhibition represent an important target in the treatment of patients with FD nephropathy. Nonetheless, our data show that RAS inhibition in our patients was not optimal, since its maximization determined a significant decrease in urinary protein excretion; this strongly suggests that medical intervention in these patients should be more aggressive.
Another important conclusion of our study is that PCT does not affect BP; this means that the reduction of proteinuria is not BP dependent.
The significant antiproteinuric effect of PCT was not impaired by major adverse effects, thus extending to this subgroup of high-risk and poly-treated patients the favourable safety profile of PCT previously reported [8] [9] [10] [11] [12] [16] [17] [18] . PTH and alkaline phosphatase (ALP) remained in the normal range in most patients. This finding supports the experimental evidence that low-dose PCT, given in the absence of exogenous calcium loading, is not associated to excessive suppression of bone turnover [19] .
Interpretation of results is limited by the small sample size and the absence of control group; nevertheless, the remarkable antiproteinuric response and the recovery of proteinuria to baseline after 3 months of drug withdrawal support the validity of our observations. Regarding the recovery of proteinuria after drug withdrawal, however, we cannot exclude some degree of escape of proteinuria which is not an uncommon finding when inhibition of RAS is intensified [20, 21] . Furthermore, more prolonged follow-up is required to verify efficacy and safety of this approach over the long term. Finally, we did not assess systemic RAS activity.
In conclusion, our study suggests that, in patients with FD and persisting proteinuria despite ERT and maximal tolerated anti-RAS therapy, add-on PCT safely allows a reduction of proteinuria with a remarkable achievement of levels <0.5 g/24 h in more than two-thirds of cases. PCT therefore represents a potential additional therapeutic option to be considered when intensified anti-RAS treatment is not completely efficacious or unfeasible because of adverse effects. Whether the antiproteinuric effect of PCT translates into improvement of prognosis of these high-risk patients is worth investigating.
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R E F E R E N C E S
F I G U R E 2 : Proteinuria levels for individual patients at enrolment, before (baseline), after 1-, 3-and 6-month add-on PCT (T1, T3 and T6, respectively), and after 3-month drug withdrawal. Each patient is shown as an individual regression line.
F I G U R E 3 : Proteinuria levels measured in patients before (baseline), after add-on PCT (Month 6), and after 3-month drug withdrawal. Data are mean ± SD.
